Molecular Mechanism of Antagonism between the Y181C and E138K Mutations in HIV-1 Reverse Transcriptase

ABSTRACT Etravirine (ETR) is an expanded-spectrum nonnucleoside reverse transcriptase inhibitor (NNRTI) approved for use as an antiretroviral agent in treatment-experienced patients. Y181C and E138K in HIV-1 RT are among 20 different drug resistance mutations associated with ETR. However, E138K can be consistently selected by ETR when wild-type viruses but not viruses containing Y181C are grown in tissue culture. This study was carried out to evaluate any possible mechanisms that might explain antagonism between the Y181C and E138K mutations. Accordingly, we performed tissue culture studies to investigate the evolutionary dynamics of E138K in both a wild-type (WT) and a Y181C background. We also generated recombinant enzymes containing Y181C and E138K alone or in combination in order to study enzyme processivity, rates of processive DNA synthesis, enzyme kinetics, and susceptibility to ETR. We now show that the presence of the Y181C mutation prevented the emergence of E138K in cell culture and that the simultaneous presence of E138K and Y181C impaired each of enzyme activity, processivity, rate of processive DNA synthesis, and deoxynucleoside triphosphate (dNTP) affinity. The addition of E138K to Y181C also decreased the level of resistance to ETR compared to that obtained with Y181C alone.

[1]  T. Steitz,et al.  Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Pauwels,et al.  TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments , 2005, Journal of Virology.

[3]  D I Stuart,et al.  Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  V. Calvez,et al.  Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV‐1 Non‐nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine , 2011, ChemMedChem.

[5]  M. Wainberg,et al.  Compensation by the E138K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M184I/V Mutations , 2011, Journal of Virology.

[6]  Stephen H Hughes,et al.  In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). , 2005, Journal of medicinal chemistry.

[7]  S. L. Le Grice,et al.  Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. , 1990, European journal of biochemistry.

[8]  B. Larder.  3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors , 1992, Antimicrobial Agents and Chemotherapy.

[9]  J. Vingerhoets,et al.  Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase on Phenotypic Susceptibility and Virologic Response to Etravirine , 2011, Journal of acquired immune deficiency syndromes.

[10]  T. Talele,et al.  The beta7-beta8 loop of the p51 subunit in the heterodimeric (p66/p51) human immunodeficiency virus type 1 reverse transcriptase is essential for the catalytic function of the p66 subunit. , 2001 .

[11]  M. Wainberg.  HIV Resistance to Nevirapine and Other Non‐Nucleoside Reverse Transcriptase Inhibitors , 2003, Journal of acquired immune deficiency syndromes.

[12]  A. Caliendo,et al.  Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication , 1996, Journal of virology.

[13]  V. Calvez,et al.  Emerging Mutations and Associated Factors in Patients Displaying Treatment Failure on An Etravirine-Containing Regimen , 2012, Antiviral therapy.

[14]  W. Keulen,et al.  Reduced replication of 3TC‐resistant HIV‐1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. , 1996, The EMBO journal.

[15]  C. Cameron,et al.  [13] Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase , 1995 .

[16]  M. Wainberg,et al.  In Vitro Resistance Profile of the Candidate HIV-1 Microbicide Drug Dapivirine , 2011, Antimicrobial Agents and Chemotherapy.

[17]  N. Sluis-Cremer,et al.  Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT. , 2007, The Biochemical journal.

[18]  J. Croxtall,et al.  Etravirine , 2012, Drugs.

[19]  M. de Béthune,et al.  Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies. , 2010, AIDS research and human retroviruses.

[20]  M. Wainberg,et al.  Human Immunodeficiency Virus Type 1 Recombinant Reverse Transcriptase Enzymes Containing the G190A and Y181C Resistance Mutations Remain Sensitive to Etravirine , 2009, Antimicrobial Agents and Chemotherapy.

[21]  M. Wainberg,et al.  Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C , 2010, Retrovirology.

[22]  Ivet Bahar,et al.  Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. , 2004, Current HIV research.

[23]  M. Wainberg,et al.  Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function. , 2010, The Journal of antimicrobial chemotherapy.

[24]  R. Bambara,et al.  Strand Displacement Synthesis in the Central Polypurine Tract Region of HIV-1 Promotes DNA to DNA Strand Transfer Recombination* , 1996, The Journal of Biological Chemistry.

[25]  R. A. Spence,et al.  HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors. , 1996, Biochemistry.

[26]  S. Goff,et al.  Retroviral reverse transcriptase: synthesis, structure, and function. , 1990, Journal of acquired immune deficiency syndromes.

[27]  Yvonne Jones,et al.  Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors , 1995, Nature Structural Biology.

[28]  L. Naeger,et al.  Increased Drug Susceptibility of HIV-1 Reverse Transcriptase Mutants Containing M184V and Zidovudine-Associated Mutations: Analysis of Enzyme Processivity, Chain-Terminator Removal and Viral Replication , 2000, Antiviral therapy.

[29]  P. Boyer,et al.  Apparent Defects in Processive DNA Synthesis, Strand Transfer, and Primer Elongation of Met-184 Mutants of HIV-1 Reverse Transcriptase Derive Solely from a dNTP Utilization Defect* , 2008, Journal of Biological Chemistry.

[30]  B. Canard,et al.  The Y181C Substitution in 3′-Azido-3′-deoxythymidine-resistant Human Immunodeficiency Virus, Type 1, Reverse Transcriptase Suppresses the ATP-mediated Repair of the 3′-Azido-3′-deoxythymidine 5′-Monophosphate-terminated Primer* , 2003, Journal of Biological Chemistry.

[31]  Kamalendra Singh,et al.  Insertion of a small peptide of six amino acids into the β7–β8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities , 2002, BMC Biochemistry.

[32]  M. Wainberg,et al.  Subunit-Selective Mutational Analysis and Tissue Culture Evaluations of the Interactions of the E138K and M184I Mutations in HIV-1 Reverse Transcriptase , 2012, Journal of Virology.

[33]  A. D. Clark,et al.  Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. , 1996, Structure.

[34]  B. Herman,et al.  The Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutation I132M Confers Hypersensitivity to Nucleoside Analogs , 2009, Journal of Virology.

[35]  Dirk Jochmans,et al.  TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1 , 2009, Antimicrobial Agents and Chemotherapy.

[36]  Hilde Azijn,et al.  Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies , 2010, AIDS.

[37]  C. Crumpacker,et al.  Decreased Processivity of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) Containing Didanosine-Selected Mutation Leu74Val: a Comparative Analysis of RT Variants Leu74Val and Lamivudine-Selected Met184Val , 1999, Journal of Virology.

[38]  M. Wainberg,et al.  Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. , 1994, The Journal of biological chemistry.

[39]  M. Wainberg,et al.  Characterization of the E138K Resistance Mutation in HIV-1 Reverse Transcriptase Conferring Susceptibility to Etravirine in B and Non-B HIV-1 Subtypes , 2010, Antimicrobial Agents and Chemotherapy.

[40]  C. Cameron,et al.  Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. , 1995, Methods in enzymology.

[41]  M. Wainberg,et al.  Isolation of drug-resistant mutant HIV variants using tissue culture drug selection. , 2009, Methods in molecular biology.

[42]  M. Mouroux,et al.  Resistance profile and cross‐resistance of HIV‐1 among patients failing a non‐nucleoside reverse transcriptase inhibitor‐containing regimen * , 2001, Journal of medical virology.

[43]  D. Kuritzkes,et al.  Interaction of Reverse Transcriptase (RT) Mutations Conferring Resistance to Lamivudine and Etravirine: Effects on Fitness and RT Activity of Human Immunodeficiency Virus Type 1 , 2011, Journal of Virology.

[44]  Carrie Dykes,et al.  Mutants of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Resistant to Nonnucleoside Reverse Transcriptase Inhibitors Demonstrate Altered Rates of RNase H Cleavage That Correlate with HIV-1 Replication Fitness in Cell Culture , 2000, Journal of Virology.

[45]  D I Stuart,et al.  Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. , 1998, Biochemistry.

[46]  V. Calvez,et al.  Factors Associated with Virological Response to Etravirine in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-1-Infected Patients , 2009, Antimicrobial Agents and Chemotherapy.

[47]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.

[48]  M. Wainberg,et al.  Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. , 2003, AIDS research and human retroviruses.

[49]  K. White,et al.  The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness , 2012, Journal of acquired immune deficiency syndromes.